Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results
Our Unique Biopharma Model is Delivering on Our Third Phase of Growth and Evolution
Our Strategy: Maximizing Key Growth Drivers While Expanding Pipeline for Sustainable Growth
$1.30B(1)
$297M(2)
$7M(3)
Net Sales
(1) Net sales for year ended Dec. 31, 2019.
(2) Net sales for year ended Dec. 31, 2014.
(3) Net sales for year ended Dec. 31, 2011.
HORIZON
2011-2013
2019+
Expanding Pipeline and Therapeutic Area Focus
Maximizing KRYSTEXXA opportunity
•
• Reinvesting cash flow into TEPEZZA launch and growth
•
.
Building pipeline and presence in core therapeutic areas
11 medicines; 7 for rare diseases
Rare Disease Focus
Reinvested cash flow into acquiring rare disease portfolio
Invested in repositioning and rejuvenating KRYSTEXXA
• Built out R&D capabilities
2014-2019
•
Formation
• Created sustainable, cash-flow positive company via initial portfolio
• Built out commercial capabilities
.
IPO in 2011 with 2 medicines
6View entire presentation